JSB Market Research: Asthma Therapeutics Market to 2019

Asthma Therapeutics Market to 2019 - Breakthrough Biologics
to Enhance Treatment of Severe Asthma and Drive Market
Growth
On 8 th July 2014
GBI Research, a leading business intelligence provider, has released its latest research report,
"Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of
Severe Asthma and Drive Market Growth". The asthma market is forecast to grow marginally
over the forecast period across the leading eight developed nations, from $16.6 billion in 2012
to a projected value of $21.6 billion in 2019. This growth is expected despite the generic
erosion facing the leading brands, and is a consequence of new market entrants and a disease
prevalence that continues to rise, albeit not at rates as high as have been seen in the past.
Browse Full Report @ http://www.jsbmarketresearch.com/healthcare-medical/r-Asthma-
Therapeutics-Market-to-2019-Breakthrough-Biologics-118889
Some new, costly asthma therapies could be set to enter the asthma market, including
GlaxoSmithKline's (GSK's) recently approved Relvar (fluticasone/vilanterol), and multiple
monoclonal antibodies (mAbs). These include reslizumab, mepolizumab and lebrikizumab,
which are being developed by Teva, GSK and Roche respectively.
The mAbs, in particular, have the potential to change the asthma treatment landscape, most
notably with regards to severe forms of the disease. Although such therapy may only play the
role of an alternative treatment in the asthma treatment algorithm, their ability to reduce
exacerbation rates has strong clinical and commercial value.
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Scope
The report assesses the current asthma market, and forecasts market trends to 2019, analyzing
key drivers and barriers. The areas covered include the following -
A disease introduction, which defines the disease, including symptoms, diagnosis and treatment
Analysis of the landscape of the asthma market, including a comparison of the efficacy and
safety of the most prominent brands
Detailed analysis of the asthma pipeline, including, among other parameters, details of drug
distribution by phase, molecule type and mechanism of action. The asthma clinical trial
landscape is then analyzed, with a particular emphasis on failure rates across phases as well as
trends in clinical trial size and duration, and by mechanism of action. This section also includes
single-product forecasts for the most promising pipeline drugs.
An in-depth forecasting model for the asthma market, which considers the current marketed
therapies, in addition to the potential market entry of new products. The model consists of a
projected outcome, with high and low variance results, depending on the potential
performance of pipeline therapies.
Analysis of strategic consolidations within the asthma indication, including co-development and
licensing agreements
An overview of the drivers and barriers for the asthma market
Reasons to buy
Primarily, the report will enable clients to establish a strong understanding of the asthma
indication, helping to identify and understand market opportunities and the emerging
competitive environment. It will also enable you to -
Understand the asthma pipeline and the factors that indicate that it is becoming more
innovative. This is highlighted by the presence of numerous biologics in the pipeline, which look
set to have a major impact upon the asthma market.
Observe detailed profiles for promising pipeline products, including revenue forecasts, and gain
insights into how they are likely to compete in the market and who their main competitors will
be.
Follow the trends in asthma clinical trial size and duration in relation to industry averages. In
addition, the report will enable you to assess the potential risk of future developmental
programs for asthma therapeutics, depending on the mechanism of action, by considering the
recorded clinical trial failure rates.
Observe the potential growth patterns expected for the asthma market over the forecast
period, and identify which countries are expected to contribute the most to this growth.
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Other industries we cover:
Advertising and Media
Automotive and Parts
Consumer Goods
Healthcare and Medical
Finance and Banking
Food and Beverages
Travel and Tourism
Textiles and Clothing
SWOT Analysis
Table of Content
2. Introduction
2.1. Disease Introduction
2.2. Symptoms
2.3. Etiology
2.4. Pathophysiology
2.5. Diagnosis
2.6. Assessment of Disease Severity
2.7. Treatment
2.8. Treatment Algorithm
3. Marketed Products
3.1. Product Profiles
3.1.1. Advair Diskus (fluticasone and salmeterol) - GlaxoSmithKline
3.1.2. Symbicort (budesonide/formoterol) - AstraZeneca, Co-promotion with Astellas Pharma
Inc
3.1.3. Singulair (montelukast) - Merck & Co
3.1.4. Xolair (omalizumab) - Novartis and Genentech
3.1.5. Foradil (formoterol) - Novartis (Co-marketed by Novartis and Schering Corporation)
3.1.6. Dulera/Zenhale (mometasone/formoterol) - Merck & Co
3.1.7. Relvar/Breo - GlaxoSmithKline/Theravance
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

4. Asthma Pipeline
4.1. Overview
4.2. Mechanisms of Action in the Pipeline
4.3. Clinical Trials
4.3.1. Failure Rate
4.3.2. Clinical Trial Duration
4.3.3. Clinical Trial Size
4.3.4. Comparative Clinical Trial Metrics Analysis
4.4. Promising Pipeline Molecules
4.4.1. Reslizumab - Teva Pharmaceutical ltd
4.4.2. Mepolizumab - GlaxoSmithKline
4.4.3. Lebrikizumab - Roche/Genentech
4.4.4. Veramyst - GlaxoSmithKline
4.4.5. Andolast - Rottapharm Madaus
4.4.6. Spiriva (Tiotropium Bromide) - Boehringer Ingelheim
4.5. Heat Map of Safety and Efficacy for Pipeline and Marketed Products
5. Market Forecast to 2019
5.1. Geographical Markets
5.1.1. Global Market
5.1.2. North America
5.1.3. Top Five Countries of Europe
5.1.4. Japan
5.2. Drivers and Barriers for the Asthma Therapeutics Market
5.2.1. Drivers
5.2.2. Barriers
6. Strategic Consolidations
6.1. Major Licensing Deals
6.2. Major Co-development Deals
7. Appendix
7.1. All Pipeline Drugs by Phase
7.1.1. Discovery
7.1.2. Preclinical
7.1.3. Phase I
7.1.4. Phase II
7.1.5. Phase III
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

7.1.6. Filed
7.1.7. Undisclosed
7.2. Market Forecast to 2019
7.2.1. Global
7.2.2. US
7.2.3. Canada
7.2.4. UK
7.2.5. France
7.2.6. Germany
7.2.7. Italy
7.2.8. Spain
7.2.9. Japan
7.3. References
7.3.1. References for Pipeline Heat Map
7.3.2. References for Marketed Heat Map
7.4. Market Definitions
7.5. Abbreviations
7.6. Methodology
7.7. Coverage
7.8. Secondary Research
7.9. Therapeutic Landscape
7.10. Epidemiology-Based Forecasting
7.10.1. Analogous Forecasting Methodology
7.11. Market Size by Geography
7.11.1. Forecasting Model for Therapeutic Areas
7.12. Geographical Landscape
7.13. Pipeline Analysis
7.14. Competitive Landscape
7.14.1. Expert Panel Validation
7.15. Contact Us
7.16. Disclaimer
List of Tables
Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 0-
4 Years of Age
Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 5-
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

11 Years of Age
Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Youths ≥ 12
Years of Age and Adults
Table 4: Management of Chronic Asthma
Table 5: Management of Acute Asthma
Table 6: Asthma Therapeutics Market, Global, Pipeline, Discovery, 2013
Table 7: Asthma Therapeutics Market, Global, Pipeline, Preclinical, 2013
Table 8: Asthma Therapeutics Market, Global, Pipeline, Phase I, 2013
Table 9: Asthma Therapeutics Market, Global, Pipeline, Phase II, 2013
Table 10: Asthma Therapeutics Market, Global, Pipeline, Phase III, 2013
Table 11: Asthma Therapeutics Market, Global, Pipeline, Filed, 2013
Table 12: Asthma Therapeutics Market, Global, Pipeline, Undisclosed, 2013
Table 13: Asthma, Global, Market Forecast, 2012-2019
Table 14: Asthma, US, Market Forecast, 2012-2019
Table 15: Asthma, Canada, Market Forecast, 2012-2019
Table 16: Asthma, UK, Market Forecast, 2012-2019
Table 17: Asthma, France, Market Forecast, 2012-2019
Table 18: Asthma, Germany, Market Forecast, 2012-2019
Table 19: Asthma, Italy, Market Forecast, 2012-2019
Table 20: Asthma, Spain, Market Forecast, 2012-2019
Table 21: Asthma, Japan, Market Forecast, 2012-2019
List of Figures
Figure 1: Asthma Therapeutics Market, Global, Pipeline, 2013
Figure 2: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, 2013
Figure 3: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase I, 2013
Figure 4: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase II, 2013
Figure 5: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase III,
2013
Figure 6: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate, 2013
Figure 7: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of
Action, Phase I, 2013
Figure 8: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of
Action, Phase II, 2013
Figure 9: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of
Action, Phase III, 2013
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Figure 10: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration, 2013
Figure 11: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism,
Phase I, 2013
Figure 12: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism,
Phase II, 2013
Figure 13: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism,
Phase III, 2013
Figure 14: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size, 2013
Figure 15: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism,
Phase I, 2013
Figure 16: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism,
Phase II, 2013
Figure 17: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism,
Phase III, 2013
Figure 18: Asthma Therapeutics Market, Global, Pipeline, Mechanism of Action Heat Map, 2012
Figure 19: Asthma Therapeutics Market, Global, Reslizumab Forecast ($m), 2014-2019
Figure 20: Asthma Therapeutics Market, Global, Mepolizumab Forecast ($m), 2015-2019
Figure 21: Asthma Therapeutics Market, Global, Lebrikizumab Forecast ($m), 2015-2019
Figure 22: Asthma Therapeutics Market, Global, Veramyst Forecast ($m), 2014-2019
Figure 23: Asthma Therapeutics Market, Global, Andolast Forecast ($m), 2015-2019
Figure 24: Asthma Therapeutics Market, Global, Tiotropium Bromide Forecast ($m), 2014-2019
Figure 25: Asthma Therapeutics Market, Global, Pipeline, Efficacy Heat Map, 2013
Figure 26: Asthma Therapeutics Market, Global, Pipeline, Safety Heat Map, 2013
Figure 27: Asthma Therapeutics Market, Global, Marketed Products, Safety and Efficacy Heat
Map, 2013
Figure 28: Asthma Therapeutics Market, Global, Pipeline, Competitor Grid, 2013
Figure 29: Asthma Therapeutics Market, Global, Treatment Patterns, 2012-2019
Figure 30: Asthma Therapeutics Market, Global, Market Size, 2012-2019
Figure 31: Asthma Therapeutics Market, North America, Treatment Patterns, 2012-2019
Figure 32: Asthma Therapeutics Market, North America, Annual Cost of Treatment, 2012-2019
Figure 33: Asthma Therapeutics Market, North America, Market Size, 2012-2019
Figure 34: Asthma Therapeutics Market, Top Five EU Countries, Treatment Patterns, 2012-2019
Figure 35: Asthma Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment,
2012-2019
Figure 36: Asthma Therapeutics Market, Top Five EU Countries, Market Size ($bn), 2012-2019
Figure 37: Asthma Therapeutics Market, Japan, Treatment Patterns and Annual Cost of
Treatment, 2012-2019
Figure 38: Asthma Therapeutics Market, Japan, Market Size, 2012-2019
Figure 39: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006-2013
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Figure 40: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006-2013
Figure 41: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006-2013
Figure 42: Asthma Therapeutics Market, Global, Major Licensing Deals, Completed and
Terminated
Figure 43: Asthma Therapeutics Market, Global, Major Licensing Deals by Phase and Molecule
Type, 2006-2012
Figure 44: Asthma Therapeutics Market, Global, Major Licensing Deals, Mechanism of Action
Figure 45: Asthma Therapeutics Market, Global, Major Co-developments by Region and Value,
2006-2013
Figure 46: Asthma Therapeutics Market, Global, Major Co-developments by Year, 2006-2013
Figure 47: Asthma Therapeutics Market, Global, Major Co-developments by Phase, 2006-2013
Figure 48: Asthma Therapeutics Market, Global, Major Co-developments by Phase and
Molecule Type, 2006-2013
Figure 49: Forecasting Model for Therapeutic Areas
Related reports:
Global Wheelchair Market to 2018 - Market Size, Growth, and Forecasts in 50 Countries
Fish and Seafood Market in Moldova: Databook to 2017
Healthcare and Medical Market Research
About JSB Market Research:-
JSB market research is a leading player in the market of research report distribution. It is
one-stop-shop for all information related to market research for any sector of the industry.
Along with providing in-depth analysis though reports, JSB market research also provides
regular updates of the market though newsletters. Our reports are a well-researched work of
market researchers with an extensive knowledge and a good level of market experience.
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

To know more on Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance
Treatment of Severe Asthma and Drive Market Growth
http://www.jsbmarketresearch.com/healthcare-medical/r-Asthma-Therapeutics-Market-to-
2019-Breakthrough-Biologics-118889
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/